Skip to main content

Global COVID-19 Diagnostic Testing Market to Reach $35.64 Billion by Fourth Quarter of 2021

 The global COVID-19 diagnostic testing market is projected to reach $35.64 billion by the fourth quarter of 2021, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 23.50% during the period between the third quarter of 2020 and the fourth quarter of 2021. 

The comprehensive study of the global COVID-19 diagnostic testing market by BIS Research extensively covers the following:

Market numbers on micro-segments that are influencing the market 

More than 1500 products present in the market

Pricing data for more than 500 products

Evaluation of over 350 brands

Market share analyses for more than 20 product categories

End-user preference data for over 50 end users

Detailed global and regional market share analysis, including the scrutiny of more than 30 countries 

Study of data of more than 80 companies

The detailed study is a compilation of 32 Market Data Tables and 361 Figures spread through 369 Pages and in-depth TOC on "Global COVID-19 Diagnostic Testing Market"

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 1400+ products. 

BIS Research study indicates that the increasing number of rising cases of COVID-19 globally, inciting the development of diagnostic tests, technological innovation resulting in the market pull, significant external funding supporting market growth, and favorable regulatory scenario aiding companies to launch COVID-19 diagnostic testing products., among others, are fueling the growth of the market. 

The market intelligence by BIS Research additionally throws light on the opportunities existing in the market, such as the massive scope for adoption of COVID-19 point-of-care (POC) testing products in emerging nations that can be leveraged by players operating in the market.  

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include types of products offered, sample types used, technologies, end users, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study of the global market.

View the Report from BIS Research: Global COVID-19 Diagnostic Testing Market

The technology and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of preferred kits and assays and instruments. The study is majorly centered on the sub-segments and micro-segments of the different sample types and technology markets. The sample type segment is segmented into swabs, blood samples, urine samples, and others. Under the sample type segment, swabs have been further sub-segmented into nasopharyngeal swabs and oropharyngeal swabs.

Additionally, the technology segment has been segmented into molecular assays and immunoassays. The molecular assay segment under technology has been further sub-segmented into polymerase chain reaction (PCR) and isothermal amplification, among other segments. Also, the immunoassay segment under technology has also been sub-segmented into lateral flow immunoassays (LFIA) and enzyme immunoassay (EIA).

Emphasizing the dominance of the Asia-Pacific (APAC) in the region of COVID-19 diagnostic testing market in the third quarter of 2020 and fourth quarter of 2021, Nitish Kumar Singh, Principal Analyst at BIS Research, states, "In Asia-Pacific, several emerging and legacy diagnostics manufacturers are focusing on expanding their portfolio in diagnostics for COVID-19 testing and are actively involved in developing new technologies for the same with an aim to curb the spread of COVID-19. Moreover, the governments of the Asia-Pacific region are undertaking a number of initiatives and are offering funding to the diagnostic companies to ramp the production rates of kits and assays to meet the growing demand from various end users."

Request for a Sample: https://bisresearch.com/requestsample?id=1001&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Abbott Laboratories, BGI Group, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., CENTOGENE Holding AG, Cellex Inc., CTK Biotech, Danaher Corporation, DiaSorin S.p.A, F. Hoffmann-La Roche Ltd, Hologic Inc., GenMark Diagnostics, PerkinElmer Inc., QIAGEN N.V., Luminex Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

Manufacturers of kits and assays, and instruments, operating in the field of COVID-19 diagnostic companies

Emerging companies in the field of COVID-19 diagnostic testing to assess the market situation.

How can market intelligence on COVID-19 Diagnostic Testing add value to an organization's decision-making process?

Aid in product development

Help in targeting a segment for launching a new product

Offer go to market strategies

Support in diversifying the product portfolio basis risk and progression of technology

Help in analyzing technological substitutes and compare the specification

Aid in understanding the end-user landscape

Gain holistic views pertaining to the regions and understand the market potential of the countries.

Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies.

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...
Post a Comment
Read more

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...
Post a Comment
Read more